'''<big>Adverse effects by incidence:</big>'''<ref name = TGA>{{cite web|title=TOPAMAX® Tablets and Sprinkle Capsules PRODUCT INFORMATION|work=TGA eBusiness Services|publisher=JANSSEN-CILAG Pty Ltd|date=30 May 2013|accessdate=18 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-02205-3|format=PDF}}</ref><ref name = MSR>{{cite web|title=topiramate (Rx) - Topamax, Trokendi XR|work=Medscape Reference|publisher=WebMD|accessdate=18 November 2013|url=http://reference.medscape.com/drug/topamax-trokendi-xr-topiramate-343023}}</ref><ref name = EMC>{{cite web|title=Topiramate 100 mg film-coated Tablets|work=electronic Medicines Compendium|publisher=Sandoz Limited|date=6 March 2013|accessdate=18 November 2013|url=http://www.medicines.org.uk/emc/medicine/22416/SPC/Topiramate+100+mg+film-coated+Tablets/}}</ref><ref name = DM>{{cite web|title=TOPIRAMATE ( topiramate ) tablet TOPIRAMATE ( topiramate ) tablet [Torrent Pharmaceuticals Limited]|work=DailyMed|publisher=Torrent Pharmaceuticals Limited|date=August 2011|accessdate=18 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a4ff77b8-04bc-4edb-a085-8d6d8687f8d1}}</ref>

 


 
'''Very common (>10% incidence) adverse effects include:'''

 
{{columns-list|2|

 
* [[Dizziness]]

 
* [[Weight loss]]

 
* [[Paraesthesia]] - e.g., pins and needles

 
* [[Somnolence]]

 
* [[Nausea]]

 
* [[Diarrhoea]]

 
* [[Fatigue (medical)|Fatigue]]

 
* [[Common cold|Nasopharyngitis]] - common cold

 
* [[Depression (mood)|Depression]]

 
}}

 
'''Common (1-10% incidence) adverse effects include:'''

 
{{colbegin|4}}

 
* [[Weight gain]]

 
* [[Anaemia]]

 
* Disturbance in attention

 
* Memory impairment

 
* [[Amnesia]]

 
* [[Cognitive disorder]]

 
* [[Mental impairment]]

 
* Psychomotor skills impaired

 
* [[Convulsion]]

 
* Coordination abnormal

 
* [[Tremor]]

 
* [[Lethargy]]

 
* [[Hypoaesthesia]]

 
* [[Nystagmus]]

 
* [[Dysgeusia]]

 
* [[Balance disorder]]

 
* [[Dysarthria]]

 
* [[Intention tremor]]

 
* [[Sedation]]

 
* [[Blurred vision]]

 
* [[Diplopia]]

 
* [[Visual disturbance]]

 
* [[Vertigo]]

 
* [[Tinnitus]]

 
* [[Ear pain]]

 
* [[Dyspnoea]]

 
* [[Epistaxis]]

 
* [[Nasal congestion]]

 
* [[Rhinorrhoea]]

 
* [[Vomiting]]

 
* [[Constipation]]

 
* [[Abdominal pain|Abdominal pain upper]]

 
* [[Dyspepsia]]

 
* [[Abdominal pain]]

 
* [[Dry mouth]]

 
* [[Indigestion|Stomach discomfort]]

 
* [[Paraesthesia|Paraesthesia oral]]

 
* [[Gastritis]]

 
* [[Abdominal discomfort]]

 
* [[Nephrolithiasis]]

 
* [[Pollakisuria]]

 
* [[Dysuria]]

 
* [[Alopecia]] (hair loss)

 
* [[Rash]]

 
* [[Pruritus]]

 
* [[Arthralgia]]

 
* [[Spasm|Muscle spasms]]

 
* [[Myalgia]]

 
* [[Muscle twitching]]

 
* [[Muscular weakness]]

 
* Musculoskeletal chest pain

 
* [[Anorexia]]

 
* [[Decreased appetite]]

 
* [[Pyrexia]]

 
* [[Asthenia]]

 
* [[Irritability]]

 
* [[Gait disturbance]]

 
* [[Abnormal|Feeling abnormal]]

 
* [[Malaise]]

 
* [[Hypersensitivity]]

 
* [[Bradyphrenia]]

 
* [[Insomnia]]

 
* [[Expressive language disorder]]

 
* [[Anxiety]]

 
* [[Mental confusion|Confusional state]]

 
* [[Disorientation]]

 
* [[Aggression]]

 
* Mood altered

 
* [[Psychomotor agitation|Agitation]]

 
* [[Mood swing]]s

 
* [[Anger]]

 
* [[Abnormal behaviour]]

 
{{colend}}

 


 
Rarely, the inhibition of [[carbonic anhydrase]] may be strong enough to cause [[metabolic acidosis]] of clinical importance.<ref>{{cite journal |last1=Mirza |first1=Nasir |last2=Marson |first2=Anthony G. |last3=Pirmohamed |first3=Munir |title=Effect of topiramate on acid-base balance: extent, mechanism and effects |journal=British Journal of Clinical Pharmacology |volume=68 |pages=655–61 |year=2009 |doi=10.1111/j.1365-2125.2009.03521.x |issue=5 |pmid=19916989 |pmc=2791971}}</ref>

 


 
The U.S. [[Food and Drug Administration]] (FDA) has notified prescribers that topiramate can cause acute [[myopia]] and secondary angle closure [[glaucoma]] in a small subset of people who take topiramate regularly.<ref>{{cite web|url=http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM173936.pdf|title=IMPORTANT DRUG WARNING|format=PDF|publisher=Fda.gov|accessdate=17 October 2014}}</ref> The symptoms, which typically begin in the first month of use, include blurred vision and eye pain. Discontinuation of topiramate may halt the progression of the ocular damage, and may reverse the visual impairment.

 


 
Preliminary data suggests that, as with several other anti-epileptic drugs, topiramate carries an increased risk of congenital malformations.<ref name="pmid18645165">{{cite journal |last1=Hunt |first1=S |last2=Russell |first2=A |last3=Smithson |first3=WH |last4=Parsons |first4=L |last5=Robertson |first5=I |last6=Waddell |first6=R |last7=Irwin |first7=B |last8=Morrison |first8=PJ |last9=Morrow |first9=J |title=Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register |journal=Neurology |volume=71 |issue=4 |pages=272–6 |year=2008 |pmid=18645165 |doi=10.1212/01.wnl.0000318293.28278.33 }}</ref> This might be particularly important for women who take topiramate to prevent migraine attacks. In March 2011 the FDA notified healthcare professionals and patients of an increased risk of development of [[cleft lip]] and/or [[cleft palate]] (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy and placed it in [[Pregnancy category|Pregnancy Category]] D.<ref name="fda.gov">{{cite web|author=Report a Serious Problem |url=http://www.fda.gov/Drugs/DrugSafety/ucm245085.htm |title=FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate) |publisher=Fda.gov |date=2011-01-06 |accessdate=2013-07-11}}</ref>

 


 
Topiramate has been associated with a [[statistical significance|statistically significant]] increase in [[suicide|suicidality]],<ref>{{cite web|url=http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4344s1_09_01_Trileptal%20slides.pdf |title=Suicidality and Antiepileptic Drugs |format=PDF |accessdate=2013-07-11}}</ref> and "suicidal thoughts or actions" is now listed as one of the possible side effects of the drug "in a very small number of people, about 1 in 500."<ref name="side-effects">{{cite web|url=http://www.topamax.com/how-topamax-may-help--what-to-expect.html|archive-url=https://web.archive.org/web/20110128083201/http://www.topamax.com:80/how-topamax-may-help--what-to-expect.html|dead-url=yes|archive-date=28 January 2011|title=Possible Side Effects - TOPAMAX® (topiramate)|publisher=Topamax.xom|accessdate=17 October 2014}}</ref><ref>[https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000998/]  {{webarchive |url=https://web.archive.org/web/20100805062310/http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000998/ |date=August 5, 2010 }}</ref>

 

